List of Excipients in Branded Drug ZERIT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
State of Florida DOH Central Pharmacy	ZERIT	stavudine	53808-0656	CELLULOSE, MICROCRYSTALLINE
State of Florida DOH Central Pharmacy	ZERIT	stavudine	53808-0656	GELATIN
State of Florida DOH Central Pharmacy	ZERIT	stavudine	53808-0656	LACTOSE
State of Florida DOH Central Pharmacy	ZERIT	stavudine	53808-0656	MAGNESIUM STEARATE
State of Florida DOH Central Pharmacy	ZERIT	stavudine	53808-0656	SODIUM STARCH GLYCOLATE TYPE A POTATO

Zerit (Stavudine) Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Zerit, the former Bristol-Myers Squibb brand for stavudine, has limited commercial potential as a conventional antiretroviral because of mitochondrial toxicity, peripheral neuropathy, lipoatrophy, and the availability of better-tolerated HIV therapies. The strongest remaining opportunities are low-cost pediatric formulations, salvage-market supply in selected low- and middle-income countries, and reformulations designed to reduce dosing errors and improve stability. Patent barriers are unlikely to be the principal constraint; regulatory demand, clinical relevance, and procurement economics are more important.

What is Zerit and what is its current FDA status?

Zerit contains stavudine, a thymidine nucleoside reverse transcriptase inhibitor used with other antiretroviral drugs to treat HIV-1 infection. The FDA approved Zerit capsules in 1994. Bristol-Myers Squibb later marketed oral powder for solution and pediatric strengths.[1]

Stavudine is no longer a preferred antiretroviral. The World Health Organization removed stavudine from preferred first-line treatment because of toxicity and recommended replacement with tenofovir-based regimens.[2] The U.S. Department of Health and Human Services similarly excludes stavudine from recommended initial HIV treatment regimens.[3]

Attribute	Zerit / stavudine
Active ingredient	Stavudine
Drug class	Nucleoside reverse transcriptase inhibitor
Original sponsor	Bristol-Myers Squibb
Original U.S. approval	1994
Dosage forms	Hard capsules; oral solution powder
Historical strengths	15 mg, 20 mg, 30 mg, and 40 mg capsules
Pediatric product	Powder for oral solution
Current therapeutic position	Non-preferred and generally avoided
Regulatory pathway for new entrants	Abbreviated New Drug Application, or ANDA
Biosimilar pathway	Not applicable

What excipients are used in Zerit capsules and oral solution?

The Zerit capsule formulation uses a conventional immediate-release excipient platform. FDA labeling identifies lactose, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate in the capsule fill. The capsule shell contains gelatin and colorants, including titanium dioxide and iron oxides in certain strengths.[1]

The oral-solution product uses a separate powder-for-reconstitution platform. Its commercial value depends on chemical stability, dose uniformity after reconstitution, preservative performance, and acceptable taste for pediatric patients. The exact excipient system should be taken from the applicable approved labeling and the target market's pharmacopeial requirements before development.

Formulation function	Historical Zerit approach	Development implication
Diluent	Lactose and microcrystalline cellulose	Low-cost, familiar platform; lactose intolerance and excipient restrictions may justify substitution
Disintegration	Sodium starch glycolate	Suitable for immediate release; alternative superdisintegrants can support smaller tablets or capsules
Lubrication	Magnesium stearate	Standard choice; excessive levels can reduce dissolution
Capsule shell	Gelatin with colorants	Vegetarian or halal markets may favor hypromellose shells
Pediatric liquid vehicle	Powder for reconstitution	Requires control of sedimentation, microbial risk, taste, and post-reconstitution stability
Taste control	Not a major feature of the capsule product	Important for pediatric liquid, dispersible, or multiparticulate products

Which excipient strategies could improve a generic stavudine product?

1. Lactose-free capsule platform

A lactose-free formulation could replace lactose with mannitol, dicalcium phosphate, or additional microcrystalline cellulose. Mannitol is commercially attractive because it supports powder flow and has a mild taste, but it can produce different compression and dissolution behavior. Dicalcium phosphate may improve flow but is less flexible for low-dose fill uniformity.

The commercial benefit is modest for standard adult capsules. It becomes more relevant where public-sector tenders specify lactose-free products or where manufacturers want a single excipient platform across multiple antiretroviral products.

2. Hypromellose capsules

Hypromellose shells can address vegetarian, religious, and gelatin-avoidance requirements. They also reduce dependence on animal-derived capsule materials. The main technical issue is confirming dissolution equivalence across the full strength range, especially where low-dose fills create a high excipient-to-drug ratio.

3. Pediatric powder or granules

A pediatric product has the clearest excipient opportunity. Candidate platforms include:

• Dry powder for reconstitution
• Oral granules in unit-dose sachets
• Sprinkle capsules
• Mini-tablets
• Orally disintegrating tablets
• Taste-masked multiparticulates

Stavudine has a strong bitter taste profile typical of many nucleoside analogues. Taste masking can use polymer coating, ion-exchange resins, lipid barriers, or multiparticulate encapsulation. The formulation must preserve rapid drug release after swallowing and avoid a large increase in dosing volume.

A unit-dose sachet may have greater procurement value than a multidose bottle because it reduces caregiver measurement errors. It also improves portability and may reduce contamination after repeated opening.

4. Preservative-reduced liquid formulation

A powder for reconstitution avoids the long-term preservative burden of a ready-to-use liquid. After reconstitution, the product requires defined in-use storage and handling instructions. A reformulated product could target:

• Lower preservative concentration
• Improved microbial protection
• Longer in-use stability
• Smaller reconstitution volume
• Room-temperature storage
• Clearly marked oral syringes

Any stability improvement must be demonstrated for potency, degradation products, pH, microbial quality, sedimentation, and redispersibility.

5. Excipient systems for low-dose accuracy

Stavudine doses are low relative to many conventional oral drugs. Content uniformity can become a manufacturing issue when the active ingredient is diluted across a large capsule or sachet fill. Ordered mixing, geometric dilution, spray granulation, or carrier-based multiparticulates can improve dose distribution.

A high-functionality excipient platform may reduce batch rejection and improve automated filling. The economic value comes from yield and manufacturing consistency rather than premium pricing.

What formulations are protected by Zerit patents?

The original Zerit patent estate centered on stavudine and nucleoside analog chemistry rather than a durable modern formulation platform. The relevant U.S. composition and use patents were filed before the Hatch-Waxman era reached its current structure and are understood to have expired based on their statutory terms. FDA Orange Book records should be used to confirm any country-specific listing and pediatric exclusivity history.[4]

IP category	Historical relevance	Current commercial effect
Stavudine composition patents	Covered the active compound and related nucleoside chemistry	Historical barrier; generally expired
Capsule formulation claims	Covered conventional oral dosage forms where applicable	Limited practical barrier
Oral-solution formulation claims	Potentially covered liquid or reconstitutable presentations	Any surviving claim would require jurisdiction-specific review
Method-of-use claims	Related to HIV treatment	Clinical and regulatory relevance has declined
Manufacturing-process claims	Could cover synthesis, purification, or solid-state handling	Process freedom-to-operate remains product-specific
Trademark rights	Zerit brand	Brand use remains separate from generic stavudine approval

A manufacturer should not assume that expired drug patents eliminate all intellectual-property risk. Process patents, supplier-owned technologies, trademarks, regulatory exclusivity, and formulation patents in individual jurisdictions require separate review. For a conventional generic capsule, however, the principal barriers are unlikely to be the original Zerit patents.

When did Zerit lose exclusivity, and when can generic stavudine enter?

Zerit lost meaningful U.S. market exclusivity years ago. Stavudine is eligible for generic development through the ANDA pathway because it is a small-molecule drug with an established reference product. A biosimilar application is not relevant.

Exclusivity issue	Assessment
New chemical entity exclusivity	Expired
Original patent protection	Expired or commercially immaterial in the United States
Pediatric exclusivity	Historical and expired
Orphan exclusivity	Not the principal protection for Zerit
Generic approval pathway	ANDA
Paragraph IV risk	Low commercial relevance unless a live Orange Book patent is listed
Reference-product dependence	The applicant must establish bioequivalence to the applicable reference product

A Paragraph IV certification would have commercial significance only if an unexpired patent remained listed in the Orange Book. For a legacy product such as Zerit, an ANDA applicant is more likely to rely on Paragraph III, Paragraph IV only where a specific listed patent remains relevant, or a section viii statement for an excluded method of use.[4]

What is the Orange Book status of Zerit?

The Orange Book historically listed Zerit capsules and oral solution products under Bristol-Myers Squibb-related approvals. The commercial status of an individual listing can change through discontinuation, withdrawal, or removal of a product from active marketing.

FDA treats a discontinued product differently from a product withdrawn for safety or efficacy reasons. A discontinued dosage form can remain a reference point for regulatory purposes even when the brand is no longer actively marketed.[4]

For business planning, the key issue is whether FDA identifies a current reference listed drug for the proposed strength and dosage form. This affects bioequivalence strategy, ANDA eligibility, and the ability to develop a new pediatric presentation.

Which companies are challenging or competing with Zerit?

Generic competition historically included manufacturers such as Aurobindo, Cipla, Ranbaxy, Hetero, and other suppliers serving HIV procurement programs. Competition is now better understood as competition against alternative antiretroviral regimens rather than competition among stavudine brands.

Competitive set	Commercial position versus stavudine
Tenofovir disoproxil fumarate	Preferred replacement in many treatment settings
Zidovudine	Still used in selected combinations, including certain maternal and neonatal settings
Abacavir	Alternative nucleoside option subject to patient-specific considerations
Lamivudine and emtricitabine	Common backbone agents in modern combinations
Dolutegravir-based regimens	Current standard in many treatment guidelines
Stavudine generics	Mainly residual, price-sensitive, or exceptional-use demand

No biosimilar competitors exist because stavudine is a chemically synthesized small molecule. The relevant competitors are generic antiretrovirals and newer fixed-dose combinations.

What patent litigation and settlement agreements affect Zerit?

Zerit is a legacy small-molecule product with no prominent current U.S. litigation comparable to litigation surrounding newer HIV therapies. Historical patent disputes involving stavudine and related nucleoside chemistry may remain relevant for patent-history research but are unlikely to determine a new product's commercial prospects.

There is no clear commercial rationale for a modern settlement agreement involving the original Zerit brand. Any applicant assessing launch timing should review:

• FDA Orange Book patent listings
• Federal court dockets
• Paragraph IV notices
• USPTO continuity data
• Patent term adjustment and extension records
• Supplier agreements for coated particles or taste-masking technology

What generic launch scenarios exist for stavudine?

Scenario 1: Low-cost adult capsules

This is the simplest development path. A manufacturer could use a conventional hard-capsule formulation with lactose or a substitute diluent. The regulatory burden is manageable, but market demand is likely limited and price competition is severe.

Scenario 2: Pediatric reconstitution product

This is the most defensible formulation opportunity. A product with improved taste, reliable dose measurement, simple reconstitution, and better in-use stability could address residual pediatric procurement needs. The market is constrained by treatment-guideline movement away from stavudine.

Scenario 3: Unit-dose sachets

Sachets can improve distribution and dosing control in public-health settings. Packaging, moisture protection, and supply-chain economics determine viability. A sachet product may be more attractive for institutional procurement than for retail pharmacies.

Scenario 4: Regional or salvage-market supply

Some markets may continue to use stavudine because of cost, supply limitations, or established treatment protocols. This opportunity depends on local registration, tender eligibility, pharmacovigilance requirements, and availability of preferred alternatives.

How strong is the commercial patent estate for Zerit?

The commercial patent estate is weak relative to newer HIV medicines. Core active-ingredient protection is historical, conventional capsule excipients are not differentiated, and the original product has lost clinical preference. A new entrant's defensibility would need to come from formulation execution, procurement access, manufacturing cost, or regulatory positioning rather than broad composition-of-matter rights.

A stronger product concept would combine:

1. A pediatric dosage form.
2. Taste masking with demonstrated rapid release.
3. Low-cost, scalable manufacture.
4. High dose uniformity.
5. Stable powder for reconstitution.
6. Packaging compatible with public-sector distribution.
7. A clear regulatory basis for the selected reference product.

What licensing opportunities exist for stavudine?

Licensing opportunities are limited. The original innovator rights are unlikely to create a meaningful platform opportunity. More practical transactions could involve:

• Technology licenses for taste-masked particles
• Contract manufacturing of pediatric powders
• Regional distribution rights
• Public-health procurement partnerships
• Access to validated analytical methods
• Co-development with local generic manufacturers

A licensing deal would need to solve a specific commercial problem, such as pediatric formulation, regional registration, or supply reliability. A license based only on the Zerit brand or historical active-ingredient patents is unlikely to support premium economics.

What revenue exposure does Zerit represent?

Zerit revenue exposure for Bristol-Myers Squibb is no longer a meaningful driver of pharmaceutical sales. The product's historical value has been displaced by newer antiretroviral regimens and fixed-dose combinations. A generic manufacturer should model stavudine as a small, tender-driven market with high price sensitivity and limited brand loyalty.

The largest risks are:

• Shrinking clinical use
• Guideline-driven substitution
• Low achievable price
• Small order volumes
• Regulatory variation by country
• Toxicity-related pharmacovigilance obligations
• Inventory obsolescence
• Competition from better-supported pediatric HIV products

Key Takeaways

• Zerit is the former brand of stavudine, a legacy nucleoside reverse transcriptase inhibitor.
• The original product used conventional capsule excipients, including lactose, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.
• The best formulation opportunity is a pediatric powder, granule, sachet, or taste-masked multiparticulate product.
• Stavudine has lost clinical preference because of mitochondrial toxicity, peripheral neuropathy, and lipoatrophy.
• Core Zerit patent protection is historical; current commercial risk is driven more by regulatory demand and market contraction than by patent expiry.
• Generic products would use the ANDA pathway, not the biosimilar pathway.
• Paragraph IV risk is likely limited unless a live Orange Book patent remains listed for the targeted dosage form.
• Licensing value is concentrated in formulation technology, regional access, and manufacturing capability.
• Commercial launch economics are most plausible in price-sensitive or residual-use markets, not mainstream U.S. HIV treatment.

FAQs About Zerit Excipients and Commercial Development

Can stavudine be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could address swallowing difficulty, but taste masking, low-dose content uniformity, rapid dispersion, and acceptable mouthfeel would be critical development issues.

Is lactose-free stavudine commercially viable?

It can be developed, but lactose removal alone is unlikely to create meaningful differentiation. The commercial case improves when lactose-free design is combined with pediatric dosing, taste masking, or procurement-specific requirements.

Does stavudine require a biosimilar application?

No. Stavudine is a chemically synthesized small molecule. A generic manufacturer would generally pursue an ANDA or the applicable national generic pathway.

Could a sustained-release stavudine product create new market value?

The clinical rationale is weak because stavudine's toxicity profile limits its use. A sustained-release product would also require extensive pharmacokinetic and safety justification and would compete against better-tolerated therapies.

Are Zerit formulation patents still a major launch barrier?

They are unlikely to be the principal barrier for a conventional generic capsule. A complete launch assessment still requires review of current Orange Book listings, jurisdiction-specific process patents, supplier technologies, and trademark restrictions.

References

1. U.S. Food and Drug Administration. (1994). Zerit (stavudine) prescribing information. Bristol-Myers Squibb Company.

2. World Health Organization. (2016). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach.

3. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.